| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
122,563,000 |
| Market
Cap: |
7.61(B) |
| Last
Volume: |
8,264,325 |
Avg
Vol: |
8,241,474 |
| 52
Week Range: |
$26.88 - $108.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
108,818 |
249,559 |
426,745 |
912,388 |
| Total Sell Value |
$7,662,485 |
$17,244,968 |
$23,313,629 |
$45,059,685 |
| Total People Sold |
3 |
4 |
5 |
11 |
| Total Sell Transactions |
6 |
17 |
38 |
84 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Malik Fady Ibraham |
EVP Research & Development |
• • – |
2023-11-09 |
4 |
S |
$35.40 |
$88,500 |
D/D |
(2,500) |
150,664 |
|
-99% |
|
| Blum Robert I |
President & CEO |
• • – |
2023-10-30 |
4 |
S |
$32.17 |
$402,125 |
D/D |
(12,500) |
441,417 |
|
-101% |
|
| Blum Robert I |
President & CEO |
• • – |
2023-10-30 |
4 |
OE |
$6.67 |
$83,375 |
D/D |
12,500 |
453,917 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2023-10-16 |
4 |
S |
$33.70 |
$421,250 |
D/D |
(12,500) |
441,417 |
|
-128% |
|
| Blum Robert I |
President & CEO |
• • – |
2023-10-16 |
4 |
OE |
$6.67 |
$83,375 |
D/D |
12,500 |
453,917 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2023-10-12 |
4 |
S |
$35.89 |
$89,725 |
D/D |
(2,500) |
153,164 |
|
-126% |
|
| Blum Robert I |
President & CEO |
• • – |
2023-10-06 |
4 |
S |
$30.00 |
$375,000 |
D/D |
(12,500) |
441,417 |
|
-157% |
|
| Blum Robert I |
President & CEO |
• • – |
2023-10-06 |
4 |
OE |
$6.67 |
$83,375 |
D/D |
12,500 |
453,917 |
|
- |
|
| Kaye Edward M. Md |
Director |
• • – |
2023-10-02 |
4 |
A |
$27.88 |
$12,490 |
D/D |
448 |
19,169 |
|
- |
|
| Smith Sandford D |
Director |
• • – |
2023-10-02 |
4 |
A |
$27.88 |
$12,490 |
D/D |
448 |
18,653 |
|
- |
|
| Henderson John T |
Director |
• • – |
2023-10-02 |
4 |
A |
$27.88 |
$21,245 |
D/D |
762 |
31,818 |
|
- |
|
| Wierenga Wendall D |
Director |
• • – |
2023-10-02 |
4 |
A |
$27.88 |
$12,490 |
D/D |
448 |
18,653 |
|
- |
|
| Wysenski Nancy |
Director |
• • – |
2023-10-02 |
4 |
A |
$27.88 |
$6,245 |
D/D |
224 |
17,082 |
|
- |
|
| Harrington Robert Arthur |
Director |
• • – |
2023-10-02 |
4 |
A |
$27.88 |
$12,490 |
D/D |
448 |
11,373 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2023-09-14 |
4 |
S |
$34.86 |
$87,150 |
D/D |
(2,500) |
155,664 |
|
-139% |
|
| Blum Robert I |
President & CEO |
• • – |
2023-09-13 |
4 |
S |
$34.90 |
$436,206 |
D/D |
(12,500) |
441,417 |
|
-143% |
|
| Blum Robert I |
President & CEO |
• • – |
2023-09-13 |
4 |
OE |
$6.67 |
$83,375 |
D/D |
12,500 |
453,917 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2023-08-25 |
4 |
S |
$33.99 |
$424,875 |
D/D |
(12,500) |
441,417 |
|
-153% |
|
| Blum Robert I |
President & CEO |
• • – |
2023-08-25 |
4 |
OE |
$6.67 |
$96,275 |
D/D |
12,500 |
453,917 |
|
- |
|
| Wierenga Wendall D |
Director |
• • – |
2023-08-21 |
4 |
S |
$32.02 |
$192,760 |
D/D |
(6,020) |
18,205 |
|
-153% |
|
| Wierenga Wendall D |
Director |
• • – |
2023-08-21 |
4 |
OE |
$6.72 |
$40,454 |
D/D |
6,020 |
24,225 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2023-08-11 |
4 |
AS |
$32.37 |
$404,589 |
D/D |
(12,500) |
441,417 |
|
12% |
|
| Blum Robert I |
President & CEO |
• • – |
2023-08-11 |
4 |
OE |
$7.96 |
$119,287 |
D/D |
12,500 |
442,209 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2023-08-10 |
4 |
S |
$31.70 |
$79,250 |
D/D |
(2,500) |
158,164 |
|
-11% |
|
| Blum Robert I |
President & CEO |
• • – |
2023-08-01 |
4 |
S |
$32.63 |
$407,856 |
D/D |
(12,500) |
441,417 |
|
-7% |
|
710 Records found
|
|
Page 3 of 29 |
|
|
1.92 (3%) 
